Articles scientifiques

Thrombo-embolic events in cancer patients with impaired renal function

Auteurs : Elalamy I, Canon JL, Bols A, Lybaert W, Duck L, Jochmans K, Bosquée L, Peeters M, Awada A, Clement P, Holbrechts S, Baurain JF, Mebis J, Nortier J
Année : 2014
Journal : J Strength Cond Res
Volume : 5(4)
Pages : 202

Strategies for the empirical management of infection in cancer patients with emphasis on the emergence of resistant gram-negative bacteria.

Auteurs : Klastersky J, Georgala A
Année : 2014
Journal : Crit Rev Oncol Hematol
Volume : 92(3)
Pages : 266-78

Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): A European survey conducted by the European Society for Medical Oncology (ESMO) Young Oncologists Committee.

Auteurs : Califano R, Karamouzis MV, Banerjee S, de Azambuja E, Guarneri V, Hutka M, Jordan K, Kamposioras K, Martinelli E, Corral J, Postel-Vinay S, Preusser M, Porcu L, Torri V
Année : 2014
Journal : Lung Cancer
Volume : 85(1)
Pages : 74-80

Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: A retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy.

Auteurs : Bozovic-Spasojevic I, Ameye L, Paesmans M, Larsimont D, Di Leo A, Dolci S, Piccart-Gebhart M, de Azambuja E, Loi S
Année : 2014
Journal : Breast
Volume : 23(4)
Pages : 473-81

Foreword for the edition of Treatment Strategies

Auteurs : Awada A, Aftimos P
Année : 2014
Journal : Oncology
Volume : 4(1)
Pages : 9

Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials).

Auteurs : Bonnetain F, Bonsing B, Conroy T, Dousseau A, Glimelius B, Haustermans K, Lacaine F, Van Laethem JL, Aparicio T, Aust D, Bassi C, Berger V, Chamorey E, Chibaudel B, Dahan L, de Gramont A, Delpero JR, Dervenis C, Ducreux M, Gal J, Gerber E, Ghaneh P, Hammel P, Hendlisz A, Jooste V, Labianca R, Latouche A, Lutz M, Macarulla T, Malka D, Mauer M, Mitry E, Neoptolemos J, Pessaux P, Sauvanet A, Tabernero J, Taieb J, Van Tienhoven G, Gourgou-Bourgade S, Bellera C, Mathoulin-Pélissier S, Collette L
Année : 2014
Journal : Eur. J. Cancer
Volume : 50(17)
Pages : 2983-93

Impact of tumor sequencing on the use of anticancer drugs.

Auteurs : Thomas F, Desmedt C, Aftimos P, Awada A
Année : 2014
Journal : Curr Opin Oncol
Volume : 26(3)
Pages : 347-56

Pioneering quality assessment in European cancer centers: a data analysis of the organization for European cancer institutes accreditation and designation program.

Auteurs : Saghatchian M, Thonon F, Boomsma F, Hummel H, Koot B, Harrison C, Rajan A, de Valeriola D, Otter R, Laranja Pontes J, Lombardo C, McGrath E, Ringborg U, Tursz T, Van Harten W
Année : 2014
Journal : J Oncol Pract
Volume : 10(5)
Pages : e342-9

Neurofibromatosis type I with breast cancer: not only for women!

Auteurs : Lakshmaiah KC, Kumar AN, Purohit S, Viveka BK, Rajan KR, Zameer MA, Namitha P, Saini ML, Azim HA, Saini KS
Année : 2014
Journal : Hered Cancer Clin Pract
Volume : 12(1)
Pages : 5

Menopausal hormone therapy use in 17 European countries during the last decade.

Auteurs : Ameye L, Antoine C, Paesmans M, de Azambuja E, Rozenberg S
Année : 2014
Journal : Maturitas
Volume : 79(3)
Pages : 287-91

Bosutinib in Combination With the Aromatase Inhibitor Exemestane: A Phase II Trial in Postmenopausal Women With Previously Treated Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer.

Auteurs : Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P, Zacharchuk C, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Láng I
Année : 2014
Journal : Oncologist
Volume : 19(4)
Pages : 346-7

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.

Auteurs : de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, Untch M, Jackisch C, Lang I, Smith I, Boyle F, Xu B, Barrios CH, Perez EA, Azim HA, Kim SB, Kuemmel S, Huang CS, Vuylsteke P, Hsieh RK, Gorbunova V, Eniu A, Dreosti L, Tavartkiladze N, Gelber Rd, Eidtmann H, Baselga J
Année : 2014
Journal : Lancet Oncol
Volume : 15(10)
Pages : 1137-46

Bosutinib in Combination With the Aromatase Inhibitor Letrozole: A Phase II Trial in Postmenopausal Women Evaluating First-Line Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer.

Auteurs : Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P, Zacharchuk C, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Láng I
Année : 2014
Journal : Oncologist
Volume : 19(4)
Pages : 348-9

Tumor infiltrating lymphocytes is prognostic and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.

Auteurs : Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Desmedt C, Piccart-Gebhart M, Loibl S, Denkert C, Smyth MJ, Joensuu H, Sotiriou C
Année : 2014
Journal : Ann Oncol
Volume : 25(8)
Pages : 1544-50

Supportive care is a constant state of changing: we need to adjust for it.

Auteurs : Klastersky J
Année : 2014
Journal : Curr Opin Oncol
Volume : 26(4)
Pages : 371

Reply to C. Fontanella et Al.

Auteurs : Azim HA, de Azambuja E, Agbor-Tarh D, Bradbury I
Année : 2014
Journal : J. Clin. Oncol.
Volume : 32(30)
Pages : 3459

Controversial Issues in Early Stage Breast Cancer: a Global Collaborative Survey, supported by the European Society for Medical Oncology (ESMO).

Auteurs : Zardavas D, Ades F, Spasojevic IB, Pugliano L, Capelan M, Paesmans M, de Azambuja E, Piccart-Gebhart M
Année : 2014
Journal : Ann Oncol
Volume : 25(8)
Pages : 1558-62

The 41st David A. Karnofsky Memorial Award Lecture: Academic research worldwide--quo vadis?

Auteurs : Piccart-Gebhart M
Année : 2014
Journal : J. Clin. Oncol.
Volume : 32(4)
Pages : 347-54

A Simple and Rapid Protocol to Non-enzymatically Dissociate Fresh Human Tissues for the Analysis of Infiltrating Lymphocytes.

Auteurs : Garaud S, Gu-Trantien C, Lodewyckx JN, Boisson A, De Silva P, Buisseret L, Migliori E, Libin M, Naveaux C, Duvillier H, Willard-Gallo K
Année : 2014
Journal : J Vis Exp
Volume : null(94)

Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer.

Auteurs : Rothé F, Laes JF, Lambrechts D, Smeets D, Vincent D, Maetens M, Fumagalli D, Michiels S, Drisis S, Moerman C, Detiffe JP, Larsimont D, Awada A, Piccart-Gebhart M, Sotiriou C, Ignatiadis M
Année : 2014
Journal : Ann Oncol
Volume : 25(10)
Pages : 1959-65